Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Brickell biotech, inc. save search
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 13.26%
H: 1.2%
C: -16.0%
positive results topline biotech phase 3 iot
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
BBI | $2.12 16.04%
|
Health Technology
|
| O: 0.2%
H: 1.35%
C: 1.22%
disease phase 1 biotech iot phase 2 phase 3
Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2021-08-16 (Crawled : 14:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 2.42%
H: 0.13%
C: -5.47%
treatment biotech phase 3 iot
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2021-06-29 (Crawled : 21:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 9.68%
H: 1.96%
C: -6.74%
treatment biotech phase 3 iot enroll
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Published: 2021-06-01 (Crawled : 14:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 0.59%
H: 12.2%
C: 6.1%
results biotech phase 3 iot
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2021-04-27 (Crawled : 12:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 4.35%
H: 0.0%
C: -0.97%
treatment biotech phase 3 iot enroll
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis
Published: 2021-04-23 (Crawled : 14:15) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: -0.28%
H: 11.9%
C: 5.19%
treatment potential results biotech phase 3 iot
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX
Published: 2021-04-16 (Crawled : 14:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: -1.19%
H: 6.01%
C: 1.7%
presentation results biotech phase 3 research iot
Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Published: 2021-01-19 (Crawled : 12:03) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 2.73%
H: 2.65%
C: -0.88%
results biotech phase 3
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 1.53%
H: 0.03%
C: -1.35%
biotech phase 3
Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical
Published: 2020-06-15 (Crawled : 16:01) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 103.97%
H: 1.56%
C: -26.46%
biotech positive results phase 3
Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2020-10-06 (Crawled : 16:01) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 2.25%
H: 2.2%
C: 1.1%
biotech phase 3 treatment
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.